Herein, we will review the key clinical and laboratory features of seronegative NMOSD, highlighting the differences from AQP4-IgG+ NMOSD, MOGAD, and MS where relevant, and summarize current treatment strategies. This evidence concerns the gene AQP4 and myeloid sarcoma.